Re: Farmas USA
ONVO bajando en pre
No tengo ni idea de para dónde se va a ir. Por debajo de 5 es buen precio. La dilución fue a 4,5 la semana pasada y ya había vuelto a recuperar más de un entero y medio.
Aparece un artículo alcista en Seeking sin nada de enjundia.
http://seekingalpha.com/symbol/onvo
Otro sobre el informe trimestral:
Y yo del informe trimestral saqué la información siguiente este fin de semana:
Through June 30, 2013, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, and through revenue derived from grants or collaborative research agreements. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next 12 months.
Moreover, subsequent to June 30, 2013, the Company raised net proceeds of pproximately $43.3 million through the sale of 10,350,000 shares of its common stock in a public offering.
The Company recorded stock-based compensation expense of approximately $1,379,000 for the period from April 19, 2007 (inception) through June 30, 2013.
Expense included approximately $67,000 and $35,000 for research and development during the three months ended June 30, 2013 and 2012, respectively. General and administrative expense for the three months ended June 30, 2013 and 2012 were approximately $333,000, and $4,000, respectively. The total unrecognized compensation cost related to unvested stock option grants as of June 30, 2013 was approximately $4,816,000 and the weighted average period over which these grants areexpected to vest is 3.3 years.
As of June 30, 2013, the Company had an accumulated deficit of approximately $70.1 million. The Company also had negative cash flows from operations of approximately $2.7 million during the three months ended June 30, 2013.
Revenues
For the three months ended June 30, 2013, total revenues of approximately $0.1 million were $0.2 million or 67% below the approximately $0.3 in revenues for the same period in 2012. Collaborative research revenues for the three months ended June 30, 2013 of approximately $0.1 million decreased $0.2 million or 67% from the same period of prior year of approximately $0.3 million in revenues. This decrease reflects the
planned phasing of deliverables under the original project scope of our collaborative arrangements despite current overall increases in collaborative research activities.
Operating expenses
Operating expenses increased approximately $2.1 million or 124% in the three months ended June 30, 2013 over the same period in 2012, from approximately $1.7 million in 2012 to $3.8 million in 2013. Most significantly, relative to the same period in the prior year, the Company invested in building its research, development and administrative staff, increasing its headcount from 21 full-time employees as of June 30, 2012 to 35 full-time employees as of June 30, 2013. This resulted in an increase in payroll and benefits expenses of approximately $0.5 million or 70% over the same period in 2012. In addition, stock-based compensation increased approximately $0.8 million
«Después de nada, o después de todo/ supe que todo no era más que nada.»
